Müller Maximilian, Lee Ciaran M, Gasiunas Giedrius, Davis Timothy H, Cradick Thomas J, Siksnys Virginijus, Bao Gang, Cathomen Toni, Mussolino Claudio
Institute for Cell and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.
Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Freiburg, Germany.
Mol Ther. 2016 Mar;24(3):636-44. doi: 10.1038/mt.2015.218. Epub 2015 Dec 14.
RNA-guided nucleases (RGNs) based on the type II CRISPR-Cas9 system of Streptococcus pyogenes (Sp) have been widely used for genome editing in experimental models. However, the nontrivial level of off-target activity reported in several human cells may hamper clinical translation. RGN specificity depends on both the guide RNA (gRNA) and the protospacer adjacent motif (PAM) recognized by the Cas9 protein. We hypothesized that more stringent PAM requirements reduce the occurrence of off-target mutagenesis. To test this postulation, we generated RGNs based on two Streptococcus thermophilus (St) Cas9 proteins, which recognize longer PAMs, and performed a side-by-side comparison of the three RGN systems targeted to matching sites in two endogenous human loci, PRKDC and CARD11. Our results demonstrate that in samples with comparable on-target cleavage activities, significantly lower off-target mutagenesis was detected using St-based RGNs as compared to the standard Sp-RGNs. Moreover, similarly to SpCas9, the StCas9 proteins accepted truncated gRNAs, suggesting that the specificities of St-based RGNs can be further improved. In conclusion, our results show that Cas9 proteins with longer or more restrictive PAM requirements provide a safe alternative to SpCas9-based RGNs and hence a valuable option for future human gene therapy applications.
基于化脓性链球菌(Sp)II型CRISPR-Cas9系统的RNA引导核酸酶(RGNs)已广泛用于实验模型中的基因组编辑。然而,在一些人类细胞中报道的脱靶活性水平不容忽视,这可能会阻碍其临床应用。RGN特异性取决于引导RNA(gRNA)和Cas9蛋白识别的原间隔序列临近基序(PAM)。我们推测,更严格的PAM要求可减少脱靶诱变的发生。为了验证这一假设,我们基于两种嗜热链球菌(St)Cas9蛋白(它们识别更长的PAM)构建了RGNs,并对靶向两个人类内源性基因座PRKDC和CARD11中匹配位点的三种RGN系统进行了并行比较。我们的结果表明,在具有可比的靶向切割活性的样本中,与标准Sp-RGNs相比,使用基于St的RGNs检测到的脱靶诱变显著降低。此外,与SpCas9类似,StCas9蛋白接受截短的gRNAs,这表明基于St的RGNs的特异性可以进一步提高。总之,我们的结果表明,具有更长或更严格PAM要求的Cas9蛋白为基于SpCas9的RGNs提供了一种安全的替代方案,因此是未来人类基因治疗应用的一个有价值的选择。